Cargando…

Effect of blonanserin on cognitive and social function in acute phase Japanese schizophrenia compared with risperidone

BACKGROUND: This study aims to determine the effectiveness of blonanserin (BNS) on the cognitive and social functions of patients with schizophrenia compared with risperidone (RIS) during acute-phase (8-week) treatment. METHODS: A total of 39 schizophrenia inpatients were included in this study. The...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hori, Hikaru, Yamada, Kenji, Kamada, Dan, Shibata, Yuka, Katsuki, Asuka, Yoshimura, Reiji, Nakamura, Jun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2014
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3971945/ https://www.ncbi.nlm.nih.gov/pubmed/24707178 http://dx.doi.org/10.2147/NDT.S59861

Ejemplares similares

Effects of Continuing Oral Risperidone vs. Switching from Risperidone to Risperidone Long-Acting Injection on Cognitive Function in Stable Schizophrenia Patients: A Pilot Study
por: Hori, Hikaru, et al.
Publicado: (2018)

The Impact of Aging, Psychotic Symptoms, Medication, and Brain-Derived Neurotrophic Factor on Cognitive Impairment in Japanese Chronic Schizophrenia Patients
por: Atake, Kiyokazu, et al.
Publicado: (2018)

Serum levels of brain-derived neurotrophic factor (BDNF), proBDNF and plasma 3-methoxy-4-hydroxyphenylglycol levels in chronic schizophrenia
por: Yoshimura, Reiji, et al.
Publicado: (2016)

Relationships between brain-derived neurotrophic factor, clinical symptoms, and decision-making in chronic schizophrenia: data from the Iowa Gambling Task
por: Hori, Hikaru, et al.
Publicado: (2014)

Catechol-O-methyltransferase Val158Met genotype and the clinical responses to duloxetine treatment or plasma levels of 3-methoxy-4-hydroxyphenylglycol and homovanillic acid in Japanese patients with major depressive disorder
por: Atake, Kiyokazu, et al.
Publicado: (2015)

Blood Biomarkers Predict the Cognitive Effects of Aripiprazole in Patients with Acute Schizophrenia
por: Hori, Hikaru, et al.
Publicado: (2017)

Blonanserin vs risperidone in Japanese patients with schizophrenia: A post hoc analysis of a phase 3, 8‐week, multicenter, double‐blind, randomized controlled study
por: Harvey, Philip D., et al.
Publicado: (2019)

Risk factors for further sick leave among Japanese workers returning to work after an episode of major depressive disorder: a prospective follow-up study over 1 year
por: Hori, Hikaru, et al.
Publicado: (2019)

PM498. Investigation of feelings toward taking blonanserin and risperidone in schizophrenia patients: part 2
por: Shoji, Yoshihisa, et al.
Publicado: (2016)

Early prediction of blonanserin response in Japanese patients with schizophrenia
por: Kishi, Taro, et al.
Publicado: (2014)

Profile of blonanserin for the treatment of schizophrenia
por: Tenjin, Tomomi, et al.
Publicado: (2013)

No Association between the Response to the Addition of an Atypical Antipsychotic Drug to an SSRI or SNRI and the BDNF (Val66Met) Polymorphism in Refractory Major Depressive Disorder in Japanese Patients
por: Yoshimura, Reiji, et al.
Publicado: (2012)

Efficacy and safety of blonanserin versus risperidone in the treatment of schizophrenia: a systematic review and meta-analysis of randomized controlled trials
por: Deng, Shu-Wen, et al.
Publicado: (2023)

Long-term oral blonanserin treatment for schizophrenia: a review of Japanese long-term studies
por: Murasaki, Mitsukuni, et al.
Publicado: (2021)

Blonanserin versus haloperidol in Japanese patients with schizophrenia: A phase 3, 8‐week, double‐blind, multicenter, randomized controlled study
por: Harvey, Philip D., et al.
Publicado: (2019)

Influence of fluvoxamine on plasma interleukin-6 or clinical improvement in patients with major depressive disorder
por: Yoshimura, Reiji, et al.
Publicado: (2017)

Fluvoxamine for blonanserin-associated akathisia in patients with schizophrenia: report of five cases
por: Furuse, Tsutomu, et al.
Publicado: (2010)

Six-month treatment with atypical antipsychotic drugs decreased frontal-lobe levels of glutamate plus glutamine in early-stage first-episode schizophrenia
por: Goto, Naoki, et al.
Publicado: (2012)

Duloxetine, a Selective Noradrenaline Reuptake Inhibitor, Increased Plasma Levels of 3-Methoxy-4-hydroxyphenylglycol but Not Homovanillic Acid in Patients with Major Depressive Disorder
por: Atake, Kiyokazu, et al.
Publicado: (2014)

Does subjective sleep quality improve by a walking intervention? A real-world study in a Japanese workplace
por: Hori, Hikaru, et al.
Publicado: (2016)

Blonanserin Augmentation of Atypical Antipsychotics in Patients with Schizophrenia-Who Benefits from Blonanserin Augmentation?: An Open-Label, Prospective, Multicenter Study
por: Woo, Young Sup, et al.
Publicado: (2016)

S220. BLONANSERIN AUGMENTATION IN PATIENTS WITH SCHIZOPHRENIA – WHO IS BENEFITED FROM BLONANSERIN AUGMENTATION? AN OPEN-LABEL, PROSPECTIVE, MULTI-CENTER STUDY
por: Bahk, Won-Myong, et al.
Publicado: (2018)

PM423. Blonanserin augmentation in patients with schizophrenia – who is benefited from blonanserin augmentation?: An open-label, prospective, multicenter study
por: Woo, Young Sup, et al.
Publicado: (2016)

Modeling the Choice Between Risperidone Long-Acting Injectable and Generic Risperidone from the Perspective of a Japanese Hospital
por: Nakamura, Yusuke, et al.
Publicado: (2019)

Long-Term Safety and Efficacy of Blonanserin Transdermal Patches in Japanese Patients with Schizophrenia: A 52-Week Open-Label, Multicenter Study
por: Iwata, Nakao, et al.
Publicado: (2019)

Striatal Dopamine D(2) Receptor Occupancy Induced by Daily Application of Blonanserin Transdermal Patches: Phase II Study in Japanese Patients With Schizophrenia
por: Nishibe, Hironori, et al.
Publicado: (2020)

Serum proBDNF/BDNF and response to fluvoxamine in drug-naïve first-episode major depressive disorder patients
por: Yoshimura, Reiji, et al.
Publicado: (2014)

Serum Levels of Brain-Derived Neurotrophic Factor at 4 Weeks and Response to Treatment with SSRIs
por: Yoshimura, Reiji, et al.
Publicado: (2014)

Blonanserin-induced Mood Alteration in Schizophrenia and Schizoaffective Disorder: Two Cases
por: Min, Aran, et al.
Publicado: (2013)

Follow-up Study on Electroconvulsive Therapy in Treatment-resistant Depressed Patients after Remission: A Chart Review
por: Tokutsu, Yuki, et al.
Publicado: (2013)

RISPERIDONE IN SCHIZOPHRENIA
por: Agashe, Mohan, et al.
Publicado: (1999)

RISPERIDONE IN SCHIZOPHRENIA
por: Kumar, P.N. Suresh
Publicado: (1999)

Switching Antipsychotics to Blonanserin in Patients with Schizophrenia: An Open-label, Prospective, Multicenter Study
por: Woo, Young Sup, et al.
Publicado: (2019)

A case of schizophrenia with relapsed catatonia successfully treated with blonanserin transdermal patch
por: Hagikura, Minako, et al.
Publicado: (2023)

Switching from blonanserin tablets to blonanserin transdermal patches improves tardive dyskinesia: A case report
por: Sakai, Shintaro, et al.
Publicado: (2021)

Efficacy and Safety of Blonanserin Oral Tablet in Adolescents with Schizophrenia: A 6-Week, Randomized Placebo-Controlled Study
por: Saito, Takuya, et al.
Publicado: (2022)

A randomized trial of aripiprazole vs blonanserin for the treatment of acute schizophrenia and related disorders
por: Kishi, Taro, et al.
Publicado: (2016)

Pharmacological Treatment of Schizophrenia: Japanese Expert Consensus
por: Sakurai, Hitoshi, et al.
Publicado: (2021)

Simple and Sensitive Analysis of Blonanserin and Blonanserin C in Human Plasma by Liquid Chromatography Tandem Mass Spectrometry and Its Application
por: Zheng, Yunliang, et al.
Publicado: (2014)

RISPERIDONE IN INDIAN PATIENTS WITH SCHIZOPHRENIA
por: Duggal, Harpreet S., et al.
Publicado: (1999)

Cannot write session to /tmp/vufind_sessions/sess_rq7plmpidkid9j6cfia5prs5ek